CING
Cingulate Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.10
−2.30%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +1181.6%
- EBIT
- -39.6%
- EPS
- +13.0%
- Free cash flow
- -20.1%
- Operating cash flow
- -18.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +293.5%
- EPS
- +71.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -29.4%
- EBIT
- -27.4%
- Net income
- -35.6%
- EPS
- +59.5%
- Free cash flow
- +6.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026